Cardiovascular risk in Chinese patients with chronic kidney diseases: where do we stand?

被引：0
作者：
Hou, FF [1 ]
机构：
[1] Nanfang Med Univ, Nanfang Hosp, Div Nephrol, Guangzhou 510515, Peoples R China
来源：
CHINESE MEDICAL JOURNAL | 2005年 / 118卷 / 11期
关键词：
cardiovascular disease; chronic kidney disease; epidemiology;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：883 / 886
页数：4
相关论文
共 50 条
  • [31] Risk for recurrent cardiovascular disease events among patients with diabetes and chronic kidney disease
    Hubbard, Demetria
    Colantonio, Lisandro D.
    Rosenson, Robert S.
    Brown, Todd M.
    Jackson, Elizabeth A.
    Huang, Lei
    Orroth, Kate K.
    Reading, Stephanie
    Woodward, Mark
    Bittner, Vera
    Gutierrez, Orlando M.
    Safford, Monika M.
    Farkouh, Michael E.
    Muntner, Paul
    CARDIOVASCULAR DIABETOLOGY, 2021, 20 (01)
  • [32] Non-steroidal anti-inflammatory drugs and atherothrombotic risk in older patients: where do we stand?
    Mangoni, Arduino A.
    Reid, David M.
    Knights, Kathleen M.
    AGE AND AGEING, 2010, 39 (05) : 530 - 533
  • [33] Family history of coronary heart disease and markers of subclinical cardiovascular disease: Where do we stand?
    Pandey, Arvind K.
    Pandey, Shivda
    Blaha, Michael J.
    Agatston, Arthur
    Feldman, Theodore
    Ozner, Michael
    Santos, Raul D.
    Budoff, Matthew J.
    Blumenthal, Roger S.
    Nasir, Khurram
    ATHEROSCLEROSIS, 2013, 228 (02) : 285 - 294
  • [34] Co-treatment of lower urinary tract symptoms and cardiovascular disease - where do we stand?
    Semczuk-Kaczmarek, Karolina
    Platek, Anna E.
    Szymanski, Filip M.
    CENTRAL EUROPEAN JOURNAL OF UROLOGY, 2020, 73 (01) : 42 - 45
  • [35] Early Termination of Cardiovascular Clinical Trials Registered in ClinicalTrials.gov: Where Do We Stand?
    Pereira, Sabrina B.
    Lopes, Renato D.
    Carrion, Maria Julia
    Santucci, Eliana V.
    Soares, Rafael M.
    Abreu, Matheus O.
    Laranjeira, Ligia N.
    Ikeoka, Dimas T.
    Zazula, Ana
    Moreira, Frederico R.
    Cavalcanti, Alexandre B.
    Mesquita, Evandro T.
    Peterson, Eric D.
    Califf, Robert M.
    Berwanger, Otavio
    CIRCULATION, 2013, 128 (22)
  • [36] Colchicine in Coronary Artery Disease: Where Do We Stand?
    Bonaventura, Aldo
    Potere, Nicola
    Liberale, Luca
    Kraler, Simon
    Weber, Brittany N.
    Abbate, Antonio
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2025, 85 (04) : 243 - 247
  • [37] Infectious endocarditis in the case of cirrhosis: where do we stand?
    Allaire, Manon
    Ollivier-Hourmand, Isabelle
    Garioud, Armand
    Heng, Ratmony
    Thong Dao
    Cadranel, Jean-Francois D.
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2018, 30 (12) : 1406 - 1410
  • [38] Evidence for increased cardiovascular disease risk in patients with chronic kidney disease
    Coresh, J
    Astor, B
    Sarnak, MJ
    CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION, 2004, 13 (01) : 73 - 81
  • [39] Bladder Pain Syndrome: Where Do We Stand Now?
    Chang Kit L.
    Current Bladder Dysfunction Reports, 2014, 9 (1) : 32 - 40
  • [40] Cardio-oncology: where do we stand for in Belgium?
    Lancellotti, Patrizio
    De Pauw, Michel
    Claeys, Marc
    ACTA CARDIOLOGICA, 2021, 76 (02) : 204 - 208
12345